Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis

Author(s): Amir Mahmoud Ahmadzadeh, Rozita Khodashahi, Mahmoud Mohamadzadeh Shabestari, Mohsen Aliakbarian*, Amirhossein Sahebkar* and Mohammad-Hassan Arjmand*

Volume 20, Issue 6, 2024

Published on: 18 July, 2024

Article ID: e180724231994 Pages: 8

DOI: 10.2174/011573403X304195240715103930

Price: $65

Abstract

Background: Follistatin-like proteins (FSTLs) are adipomyokines secreted by adipocytes and myocytes. Previous studies have reported an increase in circulating FSTL1 levels in response to cardiovascular injuries. In this study, we conducted a systematic review and metaanalysis to assess the association between circulating FSTLs and Cardiovascular Diseases (CVDs).

Methods: We performed a comprehensive literature search using PubMed, Web of Science, Scopus, and Embase databases. After screening the articles, we selected eligible studies, extracted relevant data, and calculated the pooled Standardized Mean Difference (SMD). We also conducted a sensitivity analysis to identify sources of heterogeneity and assessed publication bias.

Results: Among the 577 articles initially retrieved, we included 5 studies comprising a total of 941 cases with CVDs and 446 controls. All included studies measured FSTL1 levels. The pooled SMD analysis revealed a significant difference in circulating FSTL1 levels between subjects with CVDs and control groups (SMD = 0.853, 95% CI = 0.158-1.548, P = 0.016). Heterogeneity was primarily attributed to a single study that measured FSTL1 levels in heart failure patients with preserved ejection fraction. No publication bias was observed.

Conclusion: Our findings demonstrate significantly higher levels of FSTL1 in patients with CVD compared to control subjects. This suggests that FSTL1 may have potential as a diagnostic and prognostic biomarker in CVDs. However, further well-designed studies are needed to validate its clinical utility.

[1]
Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. Med Novel Technol Dev 2019; 4: 100025.
[http://dx.doi.org/10.1016/j.medntd.2019.100025]
[2]
Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 2020; 141(22): 1742-59.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044795] [PMID: 32468833]
[3]
Sacco RL, Roth GA, Reddy KS, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. Circulation 2016; 133(23): e674-90.
[http://dx.doi.org/10.1161/CIR.0000000000000395] [PMID: 27162236]
[4]
Chung HS, Choi KM. Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders. Curr Med Chem 2018; 25(20): 2401-15.
[http://dx.doi.org/10.2174/0929867325666171205144627] [PMID: 29210643]
[5]
Walsh K. Adipokines, myokines and cardiovascular disease. Circ J 2009; 73(1): 13-8.
[http://dx.doi.org/10.1253/circj.CJ-08-0961] [PMID: 19043226]
[6]
Ansaldo AM, Montecucco F, Sahebkar A, Dallegri F, Carbone F. Epicardial adipose tissue and cardiovascular diseases. Int J Cardiol 2019; 278: 254-60.
[http://dx.doi.org/10.1016/j.ijcard.2018.09.089] [PMID: 30297191]
[7]
Görgens SW, Eckardt K, Jensen J, Drevon CA, Eckel J. Eckel JJPimb, science t. Exercise and regulation of adipokine and myokine production. Prog Mol Biol Transl Sci 2015; 135: 313-36.
[http://dx.doi.org/10.1016/bs.pmbts.2015.07.002] [PMID: 26477920]
[8]
Raschke S. Adipo-myokines: two sides of the same coin—mediators of inflammation and mediators of exercise. Mediat inflamm 2013; 2013: 320724.
[9]
Xu X, Zhang T, Mokou M, et al. Follistatin-like 1 as a novel adipomyokine related to insulin resistance and physical activity. J Clin Endocrinol Metab 2020; 105(12): e4499-509.
[http://dx.doi.org/10.1210/clinem/dgaa629] [PMID: 32894773]
[10]
Sylva M, Moorman AFM, van den Hoff MJB. Follistatin‐like 1 in vertebrate development. Birth Defects Res C Embryo Today 2013; 99(1): 61-9.
[http://dx.doi.org/10.1002/bdrc.21030] [PMID: 23723173]
[11]
Cheng KY, Liu Y, Han YG, et al. Follistatin-like protein 1 suppressed pro-inflammatory cytokines expression during neuroinflammation induced by lipopolysaccharide. J Mol Histol 2017; 48(2): 63-72.
[http://dx.doi.org/10.1007/s10735-016-9706-z] [PMID: 27913976]
[12]
Li D, Wang Y, Xu N, et al. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 2011; 13(1): R17.
[http://dx.doi.org/10.1186/ar3241] [PMID: 21303509]
[13]
Ding T, He XZ, Xu XL, Xu HY, Zhou CX, Wang YJ. Expression of serum FSTL-1 in bone metastasis of prostate cancer and its clinical implication. Nat j androl 2014; 20(12): 1090-2.
[14]
Zhang Y, Xu X, Yang Y, et al. Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites. J Breast Cancer 2018; 21(3): 267-76.
[http://dx.doi.org/10.4048/jbc.2018.21.e43] [PMID: 30275855]
[15]
Wei K, Serpooshan V, Hurtado C, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 2015; 525(7570): 479-85.
[http://dx.doi.org/10.1038/nature15372] [PMID: 26375005]
[16]
Peters MMC, Meijs TA, Gathier W, et al. Follistatin-like 1 in Cardiovascular Disease and Inflammation. Mini Rev Med Chem 2019; 19(16): 1379-89.
[http://dx.doi.org/10.2174/1389557519666190312161551] [PMID: 30864520]
[17]
Kizer JR, Patel S, Ganz P, Newman AB, Bhasin S, Lee SJ. Circulating Growth Differentiation Factors 11 and 8, Their Antagonists Follistatin and Follistatin-like-3, and Risk of Heart Failure in Elders. J Gerontol A Biol Sci Med Sci 2023.
[PMID: 37624693]
[18]
Yamazaki Y, Kishimoto Y, Saita E, et al. Association between plasma follistatin-like protein 1 levels and the presence and severity of Coronary Artery Disease. Int Heart J 2021; 62(6): 1207-12.
[http://dx.doi.org/10.1536/ihj.21-203] [PMID: 34853217]
[19]
Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 2008; 117(24): 3099-108.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.767673] [PMID: 18519848]
[20]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[21]
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14(1): 135.
[http://dx.doi.org/10.1186/1471-2288-14-135] [PMID: 25524443]
[22]
Uematsu M, Nakamura K, Nakamura T, et al. Persistent Myocardial Production of Follistatin-like 1 Is Associated With Left Ventricular Adverse Remodeling in Patients With Myocardial Infarction. J Card Fail 2020; 26(8): 733-8.
[http://dx.doi.org/10.1016/j.cardfail.2020.05.015] [PMID: 32470377]
[23]
Assadi-Khansari B, Liu S, Ajero C, Chua S, Horowitz J, Sverdlov A. Follistatin-like 3 is elevated in acute heart failure patients. Euro Heart J 2016; 25: S109-10.
[http://dx.doi.org/10.1016/j.hlc.2016.06.260]
[24]
Chen D, Untaru R, Liu S, Assafi-Khansari B, Croft A, Kelly C. Follistatin-like 3 (FSTL3). Levels in Patients With Cardiovascular Disease 2021; 30: S124.
[25]
Tanaka K, Valero-Muñoz M, Wilson RM, et al. Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci 2016; 1(4): 207-21.
[http://dx.doi.org/10.1016/j.jacbts.2016.04.002] [PMID: 27430031]
[26]
El-Armouche A, Ouchi N, Tanaka K, et al. Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail 2011; 4(5): 621-7.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.960625] [PMID: 21622850]
[27]
Widera C, Horn-Wichmann R, Kempf T, et al. Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin Chem 2009; 55(10): 1794-800.
[http://dx.doi.org/10.1373/clinchem.2009.129411] [PMID: 19574466]
[28]
Campolo J, Corradi E, Parolini M, et al. Gender-Specific Behaviour in Obesity Stages I-II: Imbalance of Aminothiol Status and Adipomyokine Profile in Subjects with Different Insulin Resistance Severity. Oxid Med Cell Longev 2021; 2021: 1-9.
[http://dx.doi.org/10.1155/2021/9713582] [PMID: 34868459]
[29]
Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005; 16(2): 73-8.
[http://dx.doi.org/10.1016/j.tem.2005.01.003] [PMID: 15734148]
[30]
Lara-Pezzi E, Felkin LE, Birks EJ, et al. Expression of follistatin-related genes is altered in heart failure. Endocrinology 2008; 149(11): 5822-7.
[http://dx.doi.org/10.1210/en.2008-0151] [PMID: 18617621]
[31]
Hu S, Liu H, Hu Z, Li L, Yang Y. Follistatin‐like 1: A dual regulator that promotes cardiomyocyte proliferation and fibrosis. J Cell Physiol 2020; 235(9): 5893-902.
[http://dx.doi.org/10.1002/jcp.29588] [PMID: 32017077]
[32]
Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 2008; 283(47): 32802-11.
[33]
Mattiotti A, Prakash S, Barnett P, van den Hoff MJB, Sciences ML. Follistatin-like 1 in development and human diseases. Cell Mol Life Sci 2018; 75(13): 2339-54.
[http://dx.doi.org/10.1007/s00018-018-2805-0] [PMID: 29594389]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy